Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
3 May 24
10-Q
2024 Q2
Quarterly report
1 May 24
8-K
Cencora Reports Fiscal 2024 Second Quarter Results
1 May 24
8-K
Entry into a Material Definitive Agreement
23 Apr 24
8-K/A
Departure of Directors or Certain Officers
15 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Mar 24
8-K
Cencora Announces Leadership Succession Plan
12 Mar 24
8-K
1.05
27 Feb 24
8-K
Entry into a Material Definitive Agreement
9 Feb 24
8-K
Cencora Closes $500 Million Senior Notes Offering
7 Feb 24
424B2
Prospectus for primary offering
7 Feb 24
8-K
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
7 Feb 24
FWP
Free writing prospectus
5 Feb 24
424B5
Prospectus supplement for primary offering
5 Feb 24
10-Q
2024 Q1
Quarterly report
31 Jan 24
8-K
Cencora Reports Fiscal 2024 First Quarter Results
31 Jan 24
ARS
2023 FY
Annual report to shareholders
29 Jan 24
DEFA14A
Additional proxy soliciting materials
29 Jan 24
DEF 14A
Definitive proxy
29 Jan 24
PRE 14A
Preliminary proxy
17 Jan 24
8-K
Departure of Directors or Certain Officers
16 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
26 Dec 23
8-K
Other Events
21 Dec 23
10-K
2023 FY
Annual report
21 Nov 23
8-K
Entry into a Material Definitive Agreement
14 Nov 23
8-K
Cencora Reports Fiscal 2023 Fourth Quarter and Year End Results
2 Nov 23
8-K
Entry into a Material Definitive Agreement
10 Oct 23
8-K
AmerisourceBergen becomes Cencora, in alignment with the company’s growing global footprint and central role in pharmaceutical access and care
30 Aug 23
8-K
Amerisourcebergen Elects Werner Baumann and Lauren Tyler to Its Board of Directors
15 Aug 23
8-K
Entry into a Material Definitive Agreement
8 Aug 23
424B7
Prospectus with selling stockholder info
7 Aug 23
424B7
Prospectus with selling stockholder info
3 Aug 23
10-Q
2023 Q3
Quarterly report
2 Aug 23
8-K
Fiscal 2023 Third Quarter Results
2 Aug 23
8-K
Entry into a Material Definitive Agreement
20 Jun 23
8-K
TPG and AmerisourceBergen Announce Completion of Acquisition of ONEONCOLOGY
9 Jun 23
SD
Conflict minerals disclosure
31 May 23
8-K
Entry into a Material Definitive Agreement
15 May 23
8-K
Entry into a Material Definitive Agreement
5 May 23
10-Q
2023 Q2
Quarterly report
2 May 23
Latest ownership filings
4
Lauren M Tyler
3 May 24
4
Werner Baumann
3 May 24
4
DENNIS M NALLY
3 May 24
4
Robert P. Mauch
17 Apr 24
4
STEVEN H COLLIS
17 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
STEVEN H COLLIS
21 Mar 24
4
Elizabeth S Campbell
20 Mar 24
144
Notice of proposed sale of securities
19 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
4
Lorence H. Kim
13 Mar 24
4
Silvana Battaglia
13 Mar 24
4
James F Cleary
13 Mar 24
4
Elizabeth S Campbell
13 Mar 24
4
DERMOT MARK DURCAN
13 Mar 24
4
RICHARD W GOCHNAUER
13 Mar 24
4
KATHLEEN W HYLE
13 Mar 24
4
LON R GREENBERG
13 Mar 24
4
DENNIS M NALLY
13 Mar 24
4
Werner Baumann
13 Mar 24
4
Redonda Miller
13 Mar 24
4
Lauren M Tyler
13 Mar 24
4
Silvana Battaglia
11 Mar 24
4
Gina Clark
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
144
Notice of proposed sale of securities
13 Feb 24
SC 13D/A
Walgreens Boots Alliance, Inc.
9 Feb 24
4
Change in insider ownership
9 Feb 24
144
Notice of proposed sale of securities
7 Feb 24
4
DENNIS M NALLY
5 Feb 24
4
Werner Baumann
5 Feb 24
4
Lauren M Tyler
5 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
4
LON R GREENBERG
17 Jan 24
4
Silvana Battaglia
8 Jan 24
4
Elizabeth S Campbell
8 Jan 24
4
Leslie E Donato
8 Jan 24